- Home
- ATOS vs FLUX Comparison
ATOS vs FLUX Comparison
Compare ATOS & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- FLUX
- Stock Information
- Founded
- ATOS 2009
- FLUX N/A
- Country
- ATOS United States
- FLUX United States
- Employees
- ATOS N/A
- FLUX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- ATOS Health Care
- FLUX Miscellaneous
- Exchange
- ATOS Nasdaq
- FLUX Nasdaq
- Market Cap
- ATOS 120.4M
- FLUX 98.5M
- IPO Year
- ATOS 2012
- FLUX N/A
- Fundamental
- Price
- ATOS $0.86
- FLUX $2.66
- Analyst Decision
- ATOS Strong Buy
- FLUX Strong Buy
- Analyst Count
- ATOS 3
- FLUX 2
- Target Price
- ATOS $6.25
- FLUX $6.00
- AVG Volume (30 Days)
- ATOS 1.3M
- FLUX 1.0M
- Earning Date
- ATOS 11-12-2025
- FLUX 09-16-2025
- Dividend Yield
- ATOS N/A
- FLUX N/A
- EPS Growth
- ATOS N/A
- FLUX N/A
- EPS
- ATOS N/A
- FLUX N/A
- Revenue
- ATOS N/A
- FLUX $66,434,000.00
- Revenue This Year
- ATOS N/A
- FLUX $8.23
- Revenue Next Year
- ATOS N/A
- FLUX $24.72
- P/E Ratio
- ATOS N/A
- FLUX N/A
- Revenue Growth
- ATOS N/A
- FLUX 9.22
- 52 Week Low
- ATOS $0.55
- FLUX $1.15
- 52 Week High
- ATOS $1.66
- FLUX $7.55
- Technical
- Relative Strength Index (RSI)
- ATOS 39.96
- FLUX 35.88
- Support Level
- ATOS $0.86
- FLUX $2.24
- Resistance Level
- ATOS $0.91
- FLUX $7.55
- Average True Range (ATR)
- ATOS 0.05
- FLUX 0.88
- MACD
- ATOS -0.02
- FLUX -0.52
- Stochastic Oscillator
- ATOS 4.01
- FLUX 7.91
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.